TY - JOUR
T1 - Quantifying Clinicians’ Diagnostic Uncertainty When Making Initial Treatment Decisions for Microbial Keratitis
AU - Corneal Ulcer Study Group
AU - Hicks, Patrice M.
AU - Singh, Karandeep
AU - Prajna, N. Venkatesh
AU - Lu, Ming Chen
AU - Niziol, Leslie M.
AU - Greenwald, Miles F.
AU - Verkade, Angela
AU - Amescua, Guillermo
AU - Farsiu, Sina
AU - Woodward, Maria A.
AU - Ahmed, Masih
AU - Al-Mohtaseb, Zaina
AU - Alvarez-Melloni, Diana
AU - Amin, Sejal
AU - Ayalew, Menen
AU - Balasubramanian, Ashwin
AU - Chamberlain, Winston
AU - Chan, Matilda
AU - Chan, Elsie
AU - Chaudhary, Meenu
AU - Chia, Thomas
AU - Chodosh, James
AU - Christy, Josephine
AU - Clements, John
AU - Dart, John
AU - Dastjerdi, Mohammad
AU - Denny, Matthew
AU - Elghobaier, Mohamed
AU - Estopinal, Chris
AU - Gandhi, Preethika
AU - Gokhale, Nikhil
AU - Hernandez, Natalie
AU - Hovakimyan, Anna
AU - Hwang, Frank
AU - Hwang, David
AU - Jaeschke, Tomas
AU - Jhanji, Vishal
AU - Karas, Faris
AU - Karp, Carol
AU - Kattana, Lakshmi
AU - Keenan, Jeremy
AU - Khandelwal, Sumitra
AU - Kim, Tyson
AU - Koo, Ellen
AU - Koreishi, Aaleya
AU - Li, Jennifer
AU - Lietman, Tom
AU - Macsai, Marian
AU - Shekhawat, Nakul
AU - Wolle, Meraf
N1 - Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Purpose: There is a need to understand physicians’ diagnostic uncertainty in the initial management of microbial keratitis (MK). This study aimed to understand corneal specialists’ diagnostic uncertainty by establishing risk thresholds for treatment of MK that could be used to inform a decision curve analysis for prediction modeling. Methods: A cross-sectional survey of corneal specialists with at least 2 years clinical experience was conducted. Clinicians provided the percentage risk at which they would always or never treat MK types (bacterial, fungal, herpetic, and amoebic) based on initial ulcer sizes and locations (<2 mm2 central, <2 mm2 peripheral, and >8 mm2 central). Results: Seventy-two of 99 ophthalmologists participated who were 50% female with an average of 14.7 (SD = 10.1) years of experience, 60% in academic practices, and 38% outside the United States. Clinicians reported they would “never” and “always” treat a <2 mm2 central MK infection if the median risk was 0% and 20% for bacterial (interquartile range, IQR = 0–5 and 5–50), 4.5% and 27.5% for herpetic (IQR = 0–10 and 10–50), 5% and 50% for fungal (IQR = 0–10 and 20–75), and 5% and 50.5% for amoebic (IQR = 0–20 and 32–80), respectively. Mixed-effects models showed lower thresholds to treat larger and central infections (P < 0.001, respectively), and thresholds to always treat differed between MK types for the United States (P < 0.001) but not international clinicians. Conclusions: Risk thresholds to treat differed by practice locations and MK types, location, and size. Researchers can use these thresholds to understand when a clinician is uncertain and to create decision support tools to guide clinicians’ treatment decisions.
AB - Purpose: There is a need to understand physicians’ diagnostic uncertainty in the initial management of microbial keratitis (MK). This study aimed to understand corneal specialists’ diagnostic uncertainty by establishing risk thresholds for treatment of MK that could be used to inform a decision curve analysis for prediction modeling. Methods: A cross-sectional survey of corneal specialists with at least 2 years clinical experience was conducted. Clinicians provided the percentage risk at which they would always or never treat MK types (bacterial, fungal, herpetic, and amoebic) based on initial ulcer sizes and locations (<2 mm2 central, <2 mm2 peripheral, and >8 mm2 central). Results: Seventy-two of 99 ophthalmologists participated who were 50% female with an average of 14.7 (SD = 10.1) years of experience, 60% in academic practices, and 38% outside the United States. Clinicians reported they would “never” and “always” treat a <2 mm2 central MK infection if the median risk was 0% and 20% for bacterial (interquartile range, IQR = 0–5 and 5–50), 4.5% and 27.5% for herpetic (IQR = 0–10 and 10–50), 5% and 50% for fungal (IQR = 0–10 and 20–75), and 5% and 50.5% for amoebic (IQR = 0–20 and 32–80), respectively. Mixed-effects models showed lower thresholds to treat larger and central infections (P < 0.001, respectively), and thresholds to always treat differed between MK types for the United States (P < 0.001) but not international clinicians. Conclusions: Risk thresholds to treat differed by practice locations and MK types, location, and size. Researchers can use these thresholds to understand when a clinician is uncertain and to create decision support tools to guide clinicians’ treatment decisions.
KW - corneal ulcer treatment
KW - decision curve analysis
KW - deep learning
KW - diagnostic uncertainty
KW - microbial keratitis
UR - http://www.scopus.com/inward/record.url?scp=85174543978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174543978&partnerID=8YFLogxK
U2 - 10.1097/ICO.0000000000003159
DO - 10.1097/ICO.0000000000003159
M3 - Article
C2 - 36256441
AN - SCOPUS:85174543978
SN - 0277-3740
VL - 42
SP - 1408
EP - 1413
JO - Cornea
JF - Cornea
IS - 11
ER -